Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 27, 2007. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on specific share transactions and trust activities rather than consolidated financial performance.
Material Changes and Transactions
The following transactions were reported for the period:
- March 23, 2007 (GSK Trust):
- Transferred 17,196 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Sold 16,106 Ordinary Shares at GBP 14.12 per share on behalf of the GlaxoSmithKline Performance Share Plan.
- Transferred 37,059 Ordinary Shares to participants in the GlaxoSmithKline Performance Share Plan.
- March 26, 2007 (GSK US Trust):
- Sold 4,087 ADRs at $55.09 per ADR on behalf of the GlaxoSmithKline Share Value Plan.
- Transferred 7,265 ADRs to participants in the GlaxoSmithKline Share Value Plan.
Management Commentary and Risks
The filing clarifies the nature of the trusts involved. The GSK Trust is a discretionary trust for employees of GlaxoSmithKline plc and subsidiaries, while the GSK US Trust is a grantor trust for employees of SmithKline Beecham Corporation and subsidiaries. Directors Dr. JP Garnier, Dr. M M Slaoui, and Mr. J S Heslop hold interests in the GSK Trust, while Dr. JP Garnier and Dr. M M Slaoui hold interests in the GSK US Trust, in the same capacity as other employees. No specific risks, contingencies, or unusual items beyond these standard trust transactions were disclosed.
Investor Verification Checklist
- Verify the total volume of shares and ADRs sold versus transferred to understand net dilution or retention.
- Confirm the transaction prices (GBP 14.12 and $55.09) against market prices on the respective dates.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 and the GlaxoSmithKline Performance Share Plan.
- Check for any subsequent filings regarding the directors' direct holdings separate from the trust interests.